Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer

(2020) Siyuan Cheng et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

(2020) Yezi Zhu et al.   ONCOGENE

LSD1: A single target to combat lineage plasticity in lethal prostate cancer

(2018) Leigh Ellis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers

(2018) Yan Zhang et al.   Nature Communications

Evolving concepts in prostatic neuroendocrine manifestations: from focal divergent differentiation to AMPHICRINE carcinoma

(2018) Shubha Bellur et al.   HUMAN PATHOLOGY

HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer

(2018) Dorhyun Johng et al.   PROSTATE

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage

(2018) Jung Wook Park et al.   SCIENCE

Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?

(2017) Susan Prendeville et al.   HISTOPATHOLOGY

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an­­d Serve as Models for Evaluating Cancer Therapeutics

(2017) Holly M. Nguyen et al.   PROSTATE

Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1

(2017) Mayuko Kanayama et al.   PROSTATE

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

(2017) Ping Mu et al.   SCIENCE

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

Multipotent Basal Stem Cells, Maintained in Localized Proximal Niches, Support Directed Long-Ranging Epithelial Flows in Human Prostates

(2017) Mohammad Moad et al.   Cell Reports

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer

(2016) Y. C. Yang et al.   CLINICAL CANCER RESEARCH

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein

(2016) Shuai Gao et al.   Cell Reports

SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer

(2015) X. Zhang et al.   CLINICAL CANCER RESEARCH

Engineering Enzymatically Activated “Molecular Grenades” for Cancer

(2015) Samuel R. Denmeade et al.   Oncotarget

Conversion of Androgen Receptor Signaling From a Growth Suppressor in Normal Prostate Epithelial Cells to an Oncogene in Prostate Cancer Cells Involves a Gain of Function in c-Myc Regulation

(2014) Donald J. Vander Griend et al.   International Journal of Biological Sciences

Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis

(2014) Hai Tao Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition ofc-MYCtranscription

(2014) Lizamma Antony et al.   PROSTATE

SOX2 expression in the developing, adult, as well as, diseased prostate

(2014) X Yu et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Tracking the clonal origin of lethal prostate cancer

(2013) Michael C. Haffner et al.   JOURNAL OF CLINICAL INVESTIGATION

p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia

(2013) J.-C. Pignon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug

(2012) W. N. Brennen et al.   JNCI-Journal of the National Cancer Institute

Germline Mutations inHOXB13and Prostate-Cancer Risk

(2012) Charles M. Ewing et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer

(2012) John T. Isaacs et al.   PROSTATE

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

(2011) Gerhardt Attard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

(2011) M. J. Evans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

NKX3.1 as a Marker of Prostatic Origin in Metastatic Tumors

(2010) Bora Gurel et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Identification of a Cell of Origin for Human Prostate Cancer

(2010) A. S. Goldstein et al.   SCIENCE

A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland

(2009) R. P. McMullin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation

(2008) D. E. Frigo et al.   MOLECULAR CANCER THERAPEUTICS